There is a great deal of emphasis on streamlining the

regulatory process to get important drugs to subjects who
need them expeditiously. This is of increasing importance
because of the trend to personalised drug development and
the realisation that classic randomised clinical trials are
becoming prohibitively expensive. Allan Wilson MD, PhD who
previously served in the position of Full Professor and Head,
Section of Addiction Psychiatry at the University of Ottawa,
shares his thoughts on compliance data in clinical research.